Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bogenrieder

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Oncogene|November 13, 2021
CHK1 inhibition exacerbates replication stress induced by IGF blockadeXiaoning Wu, Elena Seraia, Stephanie B Hatch, et al.
Journal of Cellular and Molecular Medicine|September 25, 2018
Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancerInhye Jeong, Sun Kyoung Kang, Woo Sun Kwon, et al.
Molecular Cancer Therapeutics|February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer ModelsUlrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
British Journal of Cancer|August 3, 2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancerValentine M Macaulay, Simon Lord, Syed Hussain, et al.
Cancer Research|January 29, 2021
Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase DysfunctionGuillaume Rieunier, Xiaoning Wu, Letitia E Harris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trialThomas H Fink, Rudolf M Huber, David F Heigener, et al.
JTO Clinical and Research Reports|September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase InhibitorsKeunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
Cancer Research|October 16, 2016
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth FactorsLucy Ireland, Almudena Santos, Muhammad S Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study GroupJalid Sehouli, Dirk Stengel, Philipp Harter, et al.
Cancer Research|May 9, 2018
Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor StageTamara Aleksic, Nicki Gray, Xiaoning Wu, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Oncogene|November 13, 2021
CHK1 inhibition exacerbates replication stress induced by IGF blockadeXiaoning Wu, Elena Seraia, Stephanie B Hatch, et al.
Journal of Cellular and Molecular Medicine|September 25, 2018
Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancerInhye Jeong, Sun Kyoung Kang, Woo Sun Kwon, et al.
Molecular Cancer Therapeutics|February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer ModelsUlrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
British Journal of Cancer|August 3, 2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancerValentine M Macaulay, Simon Lord, Syed Hussain, et al.
Cancer Research|January 29, 2021
Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase DysfunctionGuillaume Rieunier, Xiaoning Wu, Letitia E Harris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trialThomas H Fink, Rudolf M Huber, David F Heigener, et al.
JTO Clinical and Research Reports|September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase InhibitorsKeunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
Cancer Research|October 16, 2016
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth FactorsLucy Ireland, Almudena Santos, Muhammad S Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study GroupJalid Sehouli, Dirk Stengel, Philipp Harter, et al.
Cancer Research|May 9, 2018
Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor StageTamara Aleksic, Nicki Gray, Xiaoning Wu, et al.
Pageof 4